Rational Vaccine Design in the Time of COVID-19
- PMID: 32407707
- PMCID: PMC7219357
- DOI: 10.1016/j.chom.2020.04.022
Rational Vaccine Design in the Time of COVID-19
Abstract
As scientists consider SARS-CoV-2 vaccine design, we discuss problems that may be encountered and how to tackle them by what we term "rational vaccine design." We further discuss approaches to pan-coronavirus vaccines. We draw on experiences from recent research on several viruses including HIV and influenza, as well as coronaviruses.
Copyright © 2020 Elsevier Inc. All rights reserved.
Figures

References
-
- Bao L., Deng W., Gao H., Xiao C., Liu J., Xue J., Lv Q., Liu J., Yu P., Xu Y. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv. 2020 doi: 10.1101/2020.1103.1113.990226. - DOI
-
- Cirelli K.M., Carnathan D.G., Nogal B., Martin J.T., Rodriguez O.L., Upadhyay A.A., Enemuo C.A., Gebru E.H., Choe Y., Viviano F. Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance. Cell. 2019;177:1153–1171.e1128.. - PMC - PubMed
-
- Corti D., Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 2013;31:705–742. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous